Intestinal barrier in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1165-1179

  Antoni, Lena ^a   Nuding, Sabine ^a   Wehkamp, Jan ^a,b   Stange, Eduard F ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Antimicrobial peptide; Crohn's disease; Goblet cell; Inflammatory bowel disease; Intestinal barrier; Mucus layer; Paneth cell; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; MUCIN 2; PATTERN RECOGNITION RECEPTOR; PHOSPHATIDYLCHOLINE; POLYPEPTIDE ANTIBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; AUTOPHAGY; BIFIDOBACTERIUM; CANDIDA ALBICANS; CROHN DISEASE; DNA POLYMORPHISM; ENTEROENDOCRINE CELL; GENETIC SUSCEPTIBILITY; GOBLET CELL; HELICOBACTER HEPATICUS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; LISTERIA MONOCYTOGENES; PANETH CELL; STOMACH MUCUS; UNFOLDED PROTEIN RESPONSE; WNT SIGNALING PATHWAY;

ANTIMICROBIAL PEPTIDE; CROHN'S DISEASE; GOBLET CELL; INFLAMMATORY BOWEL DISEASE; INTESTINAL BARRIER; MUCUS LAYER; PANETH CELL; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; DYSBIOSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINAL MUCOSA; PERMEABILITY;

EID: 84893045146     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1165     Document Type: Article

References (170)

1. Wehkamp J, Stange EF. Paneth's disease. J Crohns Colitis 2010; 4: 523-531 [PMID: 21122555 DOI: 10.1016/j.crohns.2010.05.010]
2. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4607-4614 [PMID: 20826446 DOI: 10.1073/pnas.1000092107]
3. Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev 2012; 245: 147-163 [PMID: 22168418 DOI: 10.1111/j.1600-065X.2011.01078.x]
4. Hindryckx P, Laukens D. Intestinal barrier dysfunction: The primary driver of IBD? Inflammatory Bowel Disease-Advances in Pathogenesis and Management, Dr. Sami Karoui (Ed.), 2012; ISBN: 978-953-307-891-5, InTech. Available from: URL: http://www.intechopen.com/download/pdf/268396
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]
6. Gersemann M, Stange EF, Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol 2011; 17: 3198-3203 [PMID: 21912468]
7. Gill N, Wlodarska M, Finlay BB. Roadblocks in the gut: barriers to enteric infection. Cell Microbiol 2011; 13: 660-669 [PMID: 21392202 DOI: 10.1111/j.1462-5822.2011.01578.x]
8. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 362-381 [PMID: 20725949 DOI: 10.1002/ibd.21403]
9. McGuckin MA, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011; 9: 265-278 [PMID: 21407243 DOI: 10.1038/nrmicro2538]
10. Kubinak JL, Round JL. Toll-like receptors promote mutually beneficial commensal-host interactions. PLoS Pathog 2012; 8: e1002785 [PMID: 22910541 DOI: 10.1371/journal. ppat.1002785]
11. Roda G, Sartini A, Zambon E, Calafiore A, Marocchi M, Caponi A, Belluzzi A, Roda E. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol 2010; 16: 4264-4271 [PMID: 20818809 DOI: 10.3748/wjg.v16.i34.4264]
12. Sanz Y, De Palma G. Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol 2009; 28: 397-413 [PMID: 19954356 DOI: 10.3109/08830180903215613]
13. Koslowski MJ, Beisner J, Stange EF, Wehkamp J. Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol 2010; 300: 34-40 [PMID: 19850516 DOI: 10.1016/j.ijmm.2009.08.011]
14. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9: 356-368 [PMID: 21423246 DOI: 10.1038/nrmicro2546]
15. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124: 3-20; quiz 21-22 [PMID: 19560575 DOI: 10.1016/j.jaci.2009.05.038]
16. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009; 1165: 294-300 [PMID: 19538319 DOI: 10.1111/j.1749-6632.2009.04062.x]
17. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003; 17: 1709-1713 [PMID: 12865297 DOI: 10.1101/gad.267103]
18. Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, Stappenbeck TS. Wnt5a potentiates TGF-ß signaling to promote colonic crypt regeneration after tissue injury. Science 2012; 338: 108-113 [PMID: 22956684 DOI: 10.1126/science.1223821]
19. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007; 27: 7551-7559 [PMID: 17785439 DOI: 10.1128/MCB.01034-07]
20. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54: 1182-1193 [PMID: 15840688 DOI: 10.1136/gut.2004.062794]
21. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010; 135: 1-11 [PMID: 20116332 DOI: 10.1016/ j.clim.2009.12.004]
22. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16: 1024-1039 [PMID: 20030614 DOI: 10.217 4/138161210790963823]
23. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511 [PMID: 16847082 DOI: 10.1128/CMR.00056-05]
24. Auvynet C, Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 2009; 276: 6497-6508 [PMID: 19817855 DOI: 10.1111/j.1742-4658.2009.07360.x]
25. Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J 2011; 278: 3942-3951 [PMID: 21848912 DOI: 10.1111/ j.1742-4658.2011.08302.x]
26. Müller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci 2005; 62: 1297-1307 [PMID: 15971105 DOI: 10.1007/s00018-005-5034-2]
27. Hazlett L, Wu M. Defensins in innate immunity. Cell Tissue Res 2011; 343: 175-188 [PMID: 20730446 DOI: 10.1007/ s00441-010-1022-4]
28. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720 [PMID: 12949495 DOI: 10.1038/nri1180]
29. Pazgier M, Li X, Lu W, Lubkowski J. Human defensins: synthesis and structural properties. Curr Pharm Des 2007; 13: 3096-3118 [PMID: 17979752 DOI: 10.2174/138161207782110381]
30. Mallow EB, Harris A, Salzman N, Russell JP, DeBerardinis RJ, Ruchelli E, Bevins CL. Human enteric defensins. Gene structure and developmental expression. J Biol Chem 1996; 271: 4038-4045 [PMID: 8626737 DOI: 10.1074/jbc.271.8.4038]
31. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 2008; 1 Suppl 1: S67-S74 [PMID: 19079235 DOI: 10.1038/mi.2008.48]
32. Ouellette AJ. Paneth cell α-defensins in enteric innate immunity. Cell Mol Life Sci 2011; 68: 2215-2229 [PMID: 21560070 DOI: 10.1007/s00018-011-0714-6]
33. Cunliffe RN, Rose FR, Keyte J, Abberley L, Chan WC, Mahida YR. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001; 48: 176-185 [PMID: 11156637 DOI: 10.1136/gut.48.2.176]
34. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6: 447-456 [PMID: 16724099 DOI: 10.1038/nri1860]
35. Faurschou M, Kamp S, Cowland JB, Udby L, Johnsen AH, Calafat J, Winther H, Borregaard N. Prodefensins are matrix proteins of specific granules in human neutrophils. J Leukoc Biol 2005; 78: 785-793 [PMID: 15944211 DOI: 10.1189/ jlb.1104688]
36. Fahlgren A, Hammarström S, Danielsson A, Hammarström ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol 2003; 131: 90-101 [PMID: 12519391 DOI: 10.1046/j.1365-2249.2003.02035.x]
37. Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. beta-Defensin-3 and-4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol 2004; 137: 379-385 [PMID: 15270856 DOI: 10.1111/j.1365-2249.2004.02543.x]
38. Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschläger C, Feller AC, Stange EF. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 745-752 [PMID: 12169983 DOI: 10.1097/00042737-200207000-00006]
39. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003; 9: 215-223 [PMID: 12902844 DOI: 10.1097/00054725-20 0307000-00001]
40. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a saltsensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-560 [PMID: 9038346 DOI: 10.1016/ S0092-8674(00)81895-4]
41. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998; 95: 14961-14966 [PMID: 9843998 DOI: 10.1073/pnas.95.25.14961]
42. Harder J, Bartels J, Christophers E, Schröder JM. A peptide antibiotic from human skin. Nature 1997; 387: 861 [PMID: 9202117 DOI: 10.1038/43088]
43. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713 [PMID: 11085990 DOI: 10.1074/jbc.M008557200]
44. Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Stange EF, Wehkamp J. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 2011; 469: 419-423 [PMID: 21248850 DOI: 10.1038/nature09674]
45. Dann SM, Eckmann L. Innate immune defenses in the intestinal tract. Curr Opin Gastroenterol 2007; 23: 115-120 [PMID: 17268238 DOI: 10.1097/MOG.0b013e32803cadf4]
46. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996; 238: 325-332 [PMID: 8681941 DOI: 10.1111/j.1432-1033.1996.0325z.x]
47. Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense. Front Biosci 2008; 13: 3760-3767 [PMID: 18508470 DOI: 10.2741/2964]
48. Sørensen OE, Gram L, Johnsen AH, Andersson E, Bangsbøll S, Tjabringa GS, Hiemstra PS, Malm J, Egesten A, Borregaard N. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 2003; 278: 28540-28546 [PMID: 12759353 DOI: 10.1074/jbc.M301608200]
49. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004; 172: 3070-3077 [PMID: 14978112]
50. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, Bonnart C, Descargues P, Hovnanian A, Gallo RL. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20: 2068-2080 [PMID: 17012259 DOI: 10.1096/fj.06-6075com]
51. Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, Agerberth B. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res 2003; 53: 211-216 [PMID: 12538777 DOI: 10.1203/00006450-200302000-00003]
52. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, Aunis D, Metz-Boutigue MH. The Nand C-terminal fragments of ubiquitin are important for the antimicrobial activities. FASEB J 2003; 17: 776-778 [PMID: 12594174]
53. Harder J, Gläser R, Schröder JM. Human antimicrobial proteins effectors of innate immunity. J Endotoxin Res 2007; 13: 317-338 [PMID: 18182460 DOI: 10.1177/0968051907088275]
54. Kawasaki H, Iwamuro S. Potential roles of histones in host defense as antimicrobial agents. Infect Disord Drug Targets 2008; 8: 195-205 [PMID: 18782037 DOI: 10.2174/18715265108 08030195]
55. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009; 15: 100-113 [PMID: 18623167 DOI: 10.1002/ibd.20539]
56. Moran AP, Gupta A, Joshi L. Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 2011; 60: 1412-1425 [PMID: 21228430 DOI: 10.1136/gut.2010.212704]
57. Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospraytandem mass spectrometry. Scand J Gastroenterol 2004; 39: 737-742 [PMID: 15513358 DOI: 10.1080/00365520410006233]
58. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol 2012; 15: 57-62 [PMID: 22177113 DOI: 10.1016/j.mib.2011.11.002]
59. Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009; 1: 123-135 [PMID: 20375571 DOI: 10.1159/000163037]
60. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12: 319-330 [PMID: 20703838 DOI: 10.1007/ s11894-010-0131-2]
61. Allen A, Hutton DA, Pearson JP. The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Biol 1998; 30: 797-801 [PMID: 9722984 DOI: 10.1016/S1357-2725(98)00028-4]
62. Larsson JM, Karlsson H, Sjövall H, Hansson GC. A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 2009; 19: 756-766 [PMID: 19321523 DOI: 10.1093/glycob/cwp048]
63. Pearson JP, Brownlee IA. The interaction of large bowel microflora with the colonic mucus barrier. Int J Inflam 2010; 2010: 321426 [PMID: 21152122]
64. Corfield AP, Myerscough N, Bradfield N, Corfield Cdo A, Gough M, Clamp JR, Durdey P, Warren BF, Bartolo DC, King KR, Williams JM. Colonic mucins in ulcerative colitis: evidence for loss of sulfation. Glycoconj J 1996; 13: 809-822 [PMID: 8910008 DOI: 10.1007/BF00702345]
65. Shirazi T, Longman RJ, Corfield AP, Probert CS. Mucins and inflammatory bowel disease. Postgrad Med J 2000; 76: 473-478 [PMID: 10908374 DOI: 10.1136/pmj.76.898.473]
66. Hayashi T, Ishida T, Motoya S, Itoh F, Takahashi T, Hinoda Y, Imai K. Mucins and immune reactions to mucins in ulcerative colitis. Digestion 2001; 63 Suppl 1: 28-31 [PMID: 11173906 DOI: 10.1159/000051907]
67. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Büller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129 [PMID: 16831596 DOI: 10.1053/j.gastro.2006.04.020]
68. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008; 105: 15064-15069 [PMID: 18806221 DOI: 10.1073/pnas.0803124105]
69. Ambort D, Johansson ME, Gustafsson JK, Ermund A, Hansson GC. Perspectives on mucus properties and formation--lessons from the biochemical world. Cold Spring Harb Perspect Med 2012; 2: pii: a014159 [PMID: 23125206]
70. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4659-4665 [PMID: 20615996 DOI: 10.1073/pnas.1006451107]
71. Johansson ME, Thomsson KA, Hansson GC. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res 2009; 8: 3549-3557 [PMID: 19432394 DOI: 10.1021/pr9002504]
72. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262-265 [PMID: 8824194 DOI: 10.1126/science.274.5285.262]
73. Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009; 15: 1705-1720 [PMID: 19504612 DOI: 10.1002/ibd.20993]
74. Stremmel W, Ehehalt R, Staffer S, Stoffels S, Mohr A, Karner M, Braun A. Mucosal protection by phosphatidylcholine. Dig Dis 2012; 30 Suppl 3: 85-91 [PMID: 23295697 DOI: 10.1159/000342729]
75. Meyer-Hoffert U, Hornef MW, Henriques-Normark B, Axelsson LG, Midtvedt T, Pütsep K, Andersson M. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 2008; 57: 764-771 [PMID: 18250125 DOI: 10.1136/ gut.2007.141481]
76. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland EK, Hooper LV. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 2011; 334: 255-258 [PMID: 21998396 DOI: 10.1126/science.1209791]
77. Antoni L, Nuding S, Weller D, Gersemann M, Ott G, Wehkamp J, Stange EF. Human colonic mucus is a reservoir for antimicrobial peptides. J Crohns Colitis 2013; 7: e652-e664 [PMID: 23787054 DOI: 10.1016/j.crohns.2013.05.006]
78. Howell SJ, Wilk D, Yadav SP, Bevins CL. Antimicrobial polypeptides of the human colonic epithelium. Peptides 2003; 24: 1763-1770 [PMID: 15019208 DOI: 10.1016/j.peptides.2003.07.028]
79. Tollin M, Bergman P, Svenberg T, Jörnvall H, Gudmundsson GH, Agerberth B. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides 2003; 24: 523-530 [PMID: 12860195 DOI: 10.1016/S0196-9781(03)00114-1]
80. Felgentreff K, Beisswenger C, Griese M, Gulder T, Bringmann G, Bals R. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006; 27: 3100-3106 [PMID: 16963160 DOI: 10.1016/j.peptides.2006.07.018]
81. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. Salivary mucins inhibit antibacterial activity of the cathelicidinderived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 2008; 62: 329-335 [PMID: 18456648 DOI: 10.1093/jac/dkn176]
82. Kinnebrew MA, Pamer EG. Innate immune signaling in defense against intestinal microbes. Immunol Rev 2012; 245: 113-131 [PMID: 22168416 DOI: 10.1111/j.1600-065X.2011.01081. x]
83. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774 [PMID: 1681159 DOI: 10.1016/0140-6736(91)90663-A]
84. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267 [PMID: 9453485 DOI: 10.1016/S0016-5085(98)70476-7]
85. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953 [PMID: 8770866 DOI: 10.1172/JCI118878]
86. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-5231 [PMID: 9784526]
87. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis 2007; 44: 256-262 [PMID: 17173227 DOI: 10.1086/510385]
88. Lidar M, Langevitz P, Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. Isr Med Assoc J 2009; 11: 558-563 [PMID: 19960852]
89. Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2005; 77: 460-465 [PMID: 15618294 DOI: 10.1189/jlb.0904543]
90. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002; 37: 1034-1041 [PMID: 12374228 DOI: 10.1080/00365520232037822 0]
91. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. Gutassociated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-1767 [PMID: 16648155 DOI: 10.1136/gut.2005.078824]
92. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitisan overview. J Physiol Pharmacol 2009; 60 Suppl 6: 61-71 [PMID: 20224153]
93. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603 [PMID: 11385576 DOI: 10.1038/35079107]
94. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606 [PMID: 11385577 DOI: 10.1038/35079114]
95. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734 [PMID: 15692051 DOI: 10.1126/science.1104911]
96. Rehman A, Sina C, Gavrilova O, Häsler R, Ott S, Baines JF, Schreiber S, Rosenstiel P. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011; 60: 1354-1362 [PMID: 21421666 DOI: 10.1136/gut.2010.216259]
97. Petnicki-Ocwieja T, Hrncir T, Liu YJ, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, Kobayashi KS. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009; 106: 15813-15818 [PMID: 19805227 DOI: 10.1073/pnas.0907722106]
98. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H, Fellermann K, Ganz T, Stange EF, Bevins CL. Reduced Paneth cell alphadefensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102: 18129-18134 [PMID: 16330776 DOI: 10.1073/ pnas.0505256102]
99. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, MacDonald JA, Beck PL. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011; 17: 1359-1372 [PMID: 20872834 DOI: 10.1002/ ibd.21478]
100. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 2011; 32: 171-179 [PMID: 21388882 DOI: 10.1016/ j.it.2011.02.002]
101. Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, Baba N, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Fortin PR, Wither JE, Sarfati M, Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, Franchimont D. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41: 71-76 [PMID: 19098911 DOI: 10.1038/ng.285]
102. Schoultz I, Verma D, Halfvarsson J, Törkvist L, Fredrikson M, Sjöqvist U, Lördal M, Tysk C, Lerm M, Söderkvist P, Söderholm JD. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009; 104: 1180-1188 [PMID: 19319132 DOI: 10.1038/ajg.2009.29]
103. Lewis GJ, Massey DC, Zhang H, Bredin F, Tremelling M, Lee JC, Berzuini C, Parkes M. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm Bowel Dis 2011; 17: 1387-1391 [PMID: 21560198 DOI: 10.1002/ibd.21499]
104. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379-391 [PMID: 20303296 DOI: 10.1016/j.immuni.2010.03.003]
105. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192-1199 [PMID: 20442201 DOI: 10.1136/gut.2009.197822]
106. Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010; 107: 8772-8777 [PMID: 20421464 DOI: 10.1073/pnas.0905745107]
107. Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, Scheppach W, Gallo RL, Stange EF. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006; 18: 615-621 [PMID: 16702850 DOI: 10.1097/00042737-200606000-00007]
108. Schmid M, Fellermann K, Fritz P, Wiedow O, Stange EF, Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007; 81: 907-915 [PMID: 17200145 DOI: 10.1189/jlb.0906581]
109. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56: 1240-1247 [PMID: 17456510 DOI: 10.1136/ gut.2006.118646]
110. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Devière J, Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53: 987-992 [PMID: 15194649 DOI: 10.1136/gut.2003.030205]
111. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Göke B, Lohse P, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11: 645-652 [PMID: 15973118 DOI: 10.1097/01.MIB.0000168372.94907.d2]
112. Hume GE, Fowler EV, Doecke J, Simms LA, Huang N, Palmieri O, Griffiths LR, Florin TH, Annese V, RadfordSmith GL. Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflamm Bowel Dis 2008; 14: 585-590 [PMID: 18213697 DOI: 10.1002/ibd.20362]
113. Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 2007; 76: 196-202 [PMID: 18174680 DOI: 10.1159/000112646]
114. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V, Odes S, Binder V, Munkholm P, Moum B, Stockbrügger R, Langholz E. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007; 13: 24-32 [PMID: 17206636 DOI: 10.1002/ibd.20047]
115. Rigoli L, Romano C, Caruso RA, Lo Presti MA, Di Bella C, Procopio V, Lo Giudice G, Amorini M, Costantino G, Sergi MD, Cuppari C, Calabro GE, Gallizzi R, Salpietro CD, Fries W. Clinical significance of NOD2/CARD15 and Tolllike receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4454-4461 [PMID: 18680223 DOI: 10.3748/wjg.14.4454]
116. Wehkamp J, Wang G, Kübler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/ Tcf-4. J Immunol 2007; 179: 3109-3118 [PMID: 17709525]
117. Koslowski MJ, Kübler I, Chamaillard M, Schaeffeler E, Reinisch W, Wang G, Beisner J, Teml A, Peyrin-Biroulet L, Winter S, Herrlinger KR, Rutgeerts P, Vermeire S, Cooney R, Fellermann K, Jewell D, Bevins CL, Schwab M, Stange EF, Wehkamp J. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One 2009; 4: e4496 [PMID: 19221600 DOI: 10.1371/journal.pone.0004496]
118. Koslowski MJ, Teltschik Z, Beisner J, Schaeffeler E, Wang G, Kübler I, Gersemann M, Cooney R, Jewell D, Reinisch W, Vermeire S, Rutgeerts P, Schwab M, Stange EF, Wehkamp J. Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet 2012; 8: e1002523 [PMID: 22393312 DOI: 10.1371/journal. pgen.1002523]
119. Gersemann M, Wehkamp J, Fellermann K, Stange EF. Crohn 's disease--defect in innate defence. World J Gastroenterol 2008; 14: 5499-5503 [PMID: 18810765 DOI: 10.3748/wjg.14.5499]
120. Bertolotti A, Wang X, Novoa I, Jungreis R, Schlessinger K, Cho JH, West AB, Ron D. Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. J Clin Invest 2001; 107: 585-593 [PMID: 11238559 DOI: 10.1172/ JCI11476]
121. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134: 743-756 [PMID: 18775308 DOI: 10.1016/j.cell.2008.07.021]
122. Rolhion N, Barnich N, Bringer MA, Glasser AL, Ranc J, Hébuterne X, Hofman P, Darfeuille-Michaud A. Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut 2010; 59: 1355-1362 [PMID: 20587550 DOI: 10.1136/ gut.2010.207456]
123. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421 [PMID: 15300573 DOI: 10.1053/j.gastro.2004.04.061]
124. Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007; 117: 1566-1574 [PMID: 17525800 DOI: 10.1172/JCI30504]
125. Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1277-1283 [PMID: 17476674 DOI: 10.1002/ ibd.20176]
126. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin TH, Goodnow CC, McGuckin MA. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008; 5: e54 [PMID: 18318598 DOI: 10.1371/journal.pmed.0050054]
127. Park SW, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, Barczak AJ, Killeen N, Erle DJ. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci USA 2009; 106: 6950-6955 [PMID: 19359471 DOI: 10.1073/pnas.0808722106]
128. Zhao F, Edwards R, Dizon D, Afrasiabi K, Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B, Lipkin SM. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/mice. Dev Biol 2010; 338: 270-279 [PMID: 20025862 DOI: 10.1016/ j.ydbio.2009.12.008]
129. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N, Zeitlmann L, Grosse J, Ruf N, Nürnberg P, Costello CM, Onnie C, Mathew C, Platzer M, Schreiber S, Hampe J. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun 2006; 7: 11-18 [PMID: 16222343 DOI: 10.1038/sj.gene.6364263]
130. Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS One 2008; 3: e3391 [PMID: 18852889 DOI: 10.1371/journal.pone.0003391]
131. Shih DQ, Targan SR. Insights into IBD Pathogenesis. Curr Gastroenterol Rep 2009; 11: 473-480 [PMID: 19903423 DOI: 10.1007/s11894-009-0072-9]
132. Noda T, Yoshimori T. Molecular basis of canonical and bactericidal autophagy. Int Immunol 2009; 21: 1199-1204 [PMID: 19737785 DOI: 10.1093/intimm/dxp088]
133. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-211 [PMID: 17200669 DOI: 10.1038/ng1954]
134. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 830-832 [PMID: 17554261 DOI: 10.1038/ng2061]
135. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40: 1107-1112 [PMID: 19165925 DOI: 10.1038/ng.215]
136. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259-263 [PMID: 18849966 DOI: 10.1038/nature07416]
137. Thachil E, Hugot JP, Arbeille B, Paris R, Grodet A, Peuchmaur M, Codogno P, Barreau F, Ogier-Denis E, Berrebi D, Viala J. Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn's disease. Gastroenterology 2012; 142: 1097-1099e4 [PMID: 22285936]
138. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62 [PMID: 19898471 DOI: 10.1038/ni.1823]
139. Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A, Rhodes J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994; 35: 353-359 [PMID: 8150346 DOI: 10.1136/ gut.35.3.353]
140. Podolsky DK, Isselbacher KJ. Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology 1984; 87: 991-998 [PMID: 6090262]
141. Tysk C, Riedesel H, Lindberg E, Panzini B, Podolsky D, Järnerot G. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology 1991; 100: 419-423 [PMID: 1985038]
142. Raouf A, Parker N, Iddon D, Ryder S, Langdon-Brown B, Milton JD, Walker R, Rhodes JM. Ion exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut 1991; 32: 1139-1145 [PMID: 1955168 DOI: 10.1136/ gut.32.10.1139]
143. Bodger K, Halfvarson J, Dodson AR, Campbell F, Wilson S, Lee R, Lindberg E, Järnerot G, Tysk C, Rhodes JM. Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 2006; 55: 973-977 [PMID: 16461776 DOI: 10.1136/gut.2005.086413]
144. Larsson JM, Karlsson H, Crespo JG, Johansson ME, Eklund L, Sjövall H, Hansson GC. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis 2011; 17: 2299-2307 [PMID: 21290483 DOI: 10.1002/ibd.21625]
145. Clamp JR, Fraser G, Read AE. Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. Clin Sci (Lond) 1981; 61: 229-234 [PMID: 7261546]
146. Raouf AH, Tsai HH, Parker N, Hoffman J, Walker RJ, Rhodes JM. Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis. Clin Sci (Lond) 1992; 83: 623-626 [PMID: 1335401]
147. Tytgat KM, van der Wal JW, Einerhand AW, Büller HA, Dekker J. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem Biophys Res Commun 1996; 224: 397-405 [PMID: 8702401 DOI: 10.1006/bbrc.1996.1039]
148. Probert CS, Warren BF, Perry T, Mackay EH, Mayberry JF, Corfield AP. South Asian and European colitics show characteristic differences in colonic mucus glycoprotein type and turnover. Gut 1995; 36: 696-702 [PMID: 7797119 DOI: 10.1136/gut.36.5.696]
149. Kyo K, Parkes M, Takei Y, Nishimori H, Vyas P, Satsangi J, Simmons J, Nagawa H, Baba S, Jewell D, Muto T, Lathrop GM, Nakamura Y. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999; 8: 307-311 [PMID: 9931338 DOI: 10.1093/hmg/8.2.307]
150. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W, Schmitz G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) 2006; 84: 1055-1066 [PMID: 17058067 DOI: 10.1007/s00109-006-0100-2]
151. Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, Griger J, Fritz P, Fellermann K, Schwab M, Wehkamp J, Stange EF. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009; 77: 84-94 [PMID: 19281767 DOI: 10.1016/ j.diff.2008.09.008]
152. Pearson AD, Eastham EJ, Laker MF, Craft AW, Nelson R. Intestinal permeability in children with Crohn's disease and coeliac disease. Br Med J (Clin Res Ed) 1982; 285: 20-21 [PMID: 6805795 DOI: 10.1136/bmj.285.6334.20]
153. Arslan G, Atasever T, Cindoruk M, Yildirim IS. (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. Nucl Med Commun 2001; 22: 997-1001 [PMID: 11505209 DOI: 10.1097/00006231-200109000-00009]
154. Welcker K, Martin A, Kölle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004; 9: 456-460 [PMID: 15546811]
155. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986; 105: 883-885 [PMID: 3777713 DOI: 10.7326/0003-4819-105-6-883]
156. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993; 104: 1627-1632 [PMID: 8500719]
157. Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995; 108: 132-137 [PMID: 7528696 DOI: 10.1016/0016-5085(95)90017-9]
158. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006; 55: 342-347 [PMID: 16000642 DOI: 10.1136/ gut.2005.065557]
159. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn' s disease. Lancet 1993; 341: 1437-1439 [PMID: 8099141 DOI: 10.1016/0140-6736(93)90882-H]
160. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 1163-1169 [PMID: 11145287 DOI: 10.1080/003655200750056637]
161. Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, Baert F, Vermeire S, Vlietinck R, Rutgeerts P. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997; 113: 802-807 [PMID: 9287971 DOI: 10.1016/S0016-5085(97)70174-4]
162. Söderholm JD, Olaison G, Lindberg E, Hannestad U, Vindels A, Tysk C, Järnerot G, Sjödahl R. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut 1999; 44: 96-100 [PMID: 9862833 DOI: 10.1136/ gut.44.1.96]
163. Breslin NP, Nash C, Hilsden RJ, Hershfield NB, Price LM, Meddings JB, Sutherland LR. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am J Gastroenterol 2001; 96: 2934-2938 [PMID: 11693329 DOI: 10.1111/j.1572-0241.2001.04684.x]
164. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012; 590: 1035-1044 [PMID: 22219336]
165. Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007; 56: 61-72 [PMID: 16822808 DOI: 10.1136/gut.2006.094375]
166. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550-564 [PMID: 16083712]
167. Sipos F, Molnár B, Zágoni T, Berczi L, Tulassay Z. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53and EGFR expression alterations. Dis Colon Rectum 2005; 48: 775-786 [PMID: 15747078 DOI: 10.1007/s10350-004-0831-5]
168. Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, Solcia E, Corazza GR. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis Colon Rectum 2003; 46: 1498-1507 [PMID: 14605569 DOI: 10.1007/ s10350-004-6802-z]
169. Goetz M, Kiesslich R. Advances of endomicroscopy for gastrointestinal physiology and diseases. Am J Physiol Gastrointest Liver Physiol 2010; 298: G797-G806 [PMID: 20185688 DOI: 10.1152/ajpgi.00027.2010]
170. Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C, Allen T, Neurath MF, Shroyer NF, Montrose MH, Watson AJ. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 2007; 133: 1769-1778 [PMID: 18054549 DOI: 10.1053/ j.gastro.2007.09.011]